Grifols to acquire the remaining stake in Alkahest for $146m.

Grifols, a global producer of plasma-derived medicines, agreed to acquire the remaining 55% stake in Alkahest, a Silicon Valley-based biotechnology company, for $146m. "We are excited to join forces with Grifols, an industry leader in plasma-derived medicines, to realize our shared vision and mission of delivering innovative medicines for age-related diseases on an ambitious scale," Karoly Nikolich, Alkahest CEO.